Lethal Advanced Prostate Cancer Has Inherently Heterogeneity And Can Spread From Other Metastatic Sites

We still have a lot to learn about how prostate cancer actually spreads, or metastasizes. Current theory holds that the primary tumor is probably most responsible for the development of distant metastases. In a new genomic analysis of tissue performed at the Johns Hopkins University using tissue from prostate cancer patients this paradigm has been [...]

Liver Metastases and ECF – A Possible Treatment In A Not Good Situation

Liver metastases are uncommon in men with castrate resistant prostate cancer (CRPC). Having liver metastases is associated with more serious disease and shorter survival. How to treat men with liver metastases is still not very clear. It is felt that more active treatment might benefit these men. A standard regimen for treating gastric cancer is [...]

Doctoral Student Develops A Device That Provides An Up-Close Look At Cancer’s Movement In The Body

Sometimes scientific research is amazing! We are so lucky to have so many brilliant and gifted young people interested in conquering cancer. One of these brilliant young people is a doctoral student at Johns Hopkins, Andrew Wong. Mr Wong is a Ph.D. student studying materials science and engineering. Along with his facility advisor he has [...]

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

ASCO 2014 – Where the Tumors Are Located Influences Survival

ASCO has become a little more interesting for prostate cancer. Today's item is about a mega-analysis that confirms that the site of metastatic tumors will  powerfully predict overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC). Older and smaller studies had previously suggested that the metastatic site is prognostic for OS.  This [...]

Statins Might Inhibit Prostate Cancer from Invading Bones

One of the more recent conversations surrounding prostate cancer treatment that we have been hearing involves the use of the anti-cholesterol drugs or statins.   The conversation, whether or not statins might be a good treatment option for men with both localized disease and as an alternative to hormone treatment (ADT) for men with advanced prostate [...]

Prevalence of Fractures Among Men with Stage IV Prostate Cancer

Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis.  This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]

Zoledronic Acid (ZA) in Castrate Sensitive Prostate Cancer Does Not Prove To Be Advantageous

One thing I have noticed at some of the support groups I run is that there seems to be a very uneven distribution of when men start taking Zoledronic Acid (ZA). Hormone therapy (ADT) has many negative side effects and the loss of bone mineral density (thinning of the bones) that ZA (and similar drugs) [...]

Can You Ever Be Re-Treated With Xofigo? Finding The Answer With A New Clinical Trial

Now that Radium-223 Dichloride (Xofigo) has been approved by the FDA for use in men with castrate resistant prostate cancer with bone metastases we will begin to see the actual treatments happening. The next question in the process that will arise is whether or not it is safe and effective to re-treat an individual with [...]

Video Description of the the C-11 Choline Scan by Dr. E. Kwon From the PCRI Conference

At last year's PCRI Patient Conference Dr. Eugene Kwon from the Mayo Clinic gave a talk about the use of the C-11 Choline PET Scan for me with castrate resistant prostate cancer who have had a recurrence. Specifically, he described his patients as "Failure Patients" or advanced prostate cancer patients who have failed primary treatments [...]